Roger Bruggemann
Roger Bruggemann
Unknown affiliation
Verified email at
Cited by
Cited by
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
AJ Ullmann, JM Aguado, S Arikan-Akdagli, DW Denning, AH Groll, ...
Clinical Microbiology and Infection 24, e1-e38, 2018
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
P Koehler, M Bassetti, A Chakrabarti, SCA Chen, AL Colombo, M Hoenigl, ...
The Lancet Infectious Diseases 21 (6), e149-e162, 2021
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents
RJM Brüggemann, JWC Alffenaar, NMA Blijlevens, EM Billaud, ...
Clinical Infectious Diseases 48 (10), 1441-1458, 2009
Tackling the emerging threat of antifungal resistance to human health
MC Fisher, A Alastruey-Izquierdo, J Berman, T Bicanic, EM Bignell, ...
Nature reviews microbiology 20 (9), 557-571, 2022
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
PE Verweij, BJA Rijnders, RJM Brüggemann, E Azoulay, M Bassetti, ...
Intensive care medicine 46 (8), 1524-1535, 2020
International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus
PE Verweij, M Ananda-Rajah, D Andes, MC Arendrup, RJ Brüggemann, ...
Drug Resistance Updates 21, 30-40, 2015
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
FL van de Veerdonk, MG Netea, M van Deuren, JWM van der Meer, ...
Elife 9, e57555, 2020
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia
JA Maertens, C Girmenia, RJ Brüggemann, RF Duarte, CC Kibbler, ...
Journal of Antimicrobial Chemotherapy 73 (12), 3221-3230, 2018
Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial
M Van Den Boogaard, AJC Slooter, RJM Brüggemann, L Schoonhoven, ...
Jama 319 (7), 680-690, 2018
Antifungal drugs: what brings the future?
R Van Daele, I Spriet, J Wauters, J Maertens, T Mercier, S Van Hecke, ...
Medical mycology 57 (Supplement_3), S328-S343, 2019
Diagnosing COVID-19-associated pulmonary aspergillosis
PE Verweij, JP Gangneux, M Bassetti, RJM Brüggemann, OA Cornely, ...
The Lancet Microbe 1 (2), e53-e55, 2020
Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters
C Smit, S De Hoogd, RJM Brüggemann, CAJ Knibbe
Expert opinion on drug metabolism & toxicology 14 (3), 275-285, 2018
Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis
L Wong, Z Radić, RJM Brüggemann, N Hosea, HA Berman, P Taylor
Biochemistry 39 (19), 5750-5757, 2000
Therapeutic drug monitoring of voriconazole
RJM Brüggemann, JP Donnelly, RE Aarnoutse, A Warris, NMA Blijlevens, ...
Therapeutic drug monitoring 30 (4), 403-411, 2008
Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines
M Mikulska, D Averbuch, F Tissot, C Cordonnier, M Akova, T Calandra, ...
Journal of Infection 76 (1), 20-37, 2018
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
A Warris, T Lehrnbecher, E Roilides, E Castagnola, RJM Brüggemann, ...
Clinical Microbiology and Infection 25 (9), 1096-1113, 2019
Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene
E Mavridou, RJM Brüggemann, WJG Melchers, JW Mouton, PE Verweij
Antimicrobial agents and chemotherapy 54 (2), 860-865, 2010
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis
PE Verweij, RJM Brüggemann, E Azoulay, M Bassetti, S Blot, JB Buil, ...
Intensive care medicine 47 (8), 819-834, 2021
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections
T Tängdén, V Ramos Martín, TW Felton, EI Nielsen, S Marchand, ...
Intensive care medicine 43, 1021-1032, 2017
Drug‐drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4
AH Groll, R Townsend, A Desai, N Azie, M Jones, M Engelhardt, ...
Transplant Infectious Disease 19 (5), e12751, 2017
The system can't perform the operation now. Try again later.
Articles 1–20